What has been achieved is great. The goal is … “zero residual MR”!!! Appropriate selection of patients/MV anatomies for different centers with different levels of experience remains crucial to achieve such results. @FabienPraz @drmaisano @dralisonduncan

After the #ACC23 presentation, do not miss this webinar👉The TRILUMINATE pivotal trial: impact on practice and perspectives via @PCRonline https://t.co/wtvw8m95s4 @hahn_rt @drmaisano @FabienPraz #PCRTV @EAPCIPresident

After the Triluminate trial would you refer more 🧑‍🤝‍🧑🧑‍🤝‍🧑 with severe TR to TEER for tricuspid valve?@PCRonline @FabienPraz @AnnaSannino1985 @drmaisano @DonalErwan @hahn_rt @eromerodorta #CardioTwitter @RodrigoEstvez1 @dralisonduncan @masitges @StructuralBCN

#PCRimaging Excellent lecture on how to assess result of MV #TEER: 🫀 Multi-parametric approach for residual MR 🫀 MV gradient and area 🫀 PV flow pattern predicts prognosis 🫀 Priority to MR reduction than avoiding mild MS @PCRonline @dralisonduncan #echofirst #CardioTwitter

On demand Imaging primary mitral regurgitation and selecting the most appropriate treatment for each patient #PCRLV @masitges @patmahia @dralisonduncan You will learn more next March 2023 in Madrid PCR Imaging - stay tuned @nicolasdumonte1 @PCR @NAjmoneMarsan

Hear from @dralisonduncan on aetiology of AR, @ValveLondon on whether mild HVD matters, @Dr_Stig discusses how to present information to patients, @RichardSteeds & @mgtmccartney will debate screening for HVD, @RichardWhitloc2 discusses INR & mechanical valves...plus more!!

Congratulations to the track & programme directors #PCRLV @drtpatterson @nickaram @gabor_gt @dralisonduncan @FabienPraz @vonBardelebenRS @PCRonline @DFCapodanno @VDelgadoGarcia @modine_thomas @azeemlatib 🌟🌟🌟

#PCRLV very interesting case presented by @AnnaSannino1985 and discussions and presentations by @patmahia @dralisonduncan @Paolo24577695 @lenardconradi and excellent audience channeling questions through the app and managed by chat master @MadalinaGarbi

#PCRLV Papillary muscle rupture often presents with pulmonary edema and cardiogenic shock. 🎯 TEER was safe and effective in reducing MR and improving hemodymanic parameters 🎯 TEER should be considered as an alternative or a bridge to emergent mitral valve surgery. By M. Shuvy.

#PCRLV Resolve Study: early experience, good safety profile and reliable MR elimination in real-world at 30D 🎯 improved Sp 🎯 Improved Quality of Life 🎯 Lower average mortality rate versus predicted surgical risk score 🎯 Reliable MR elimination 🎯 Reduced LVEDV and RVSP

Wider clips preferred as first clip 84.3% subjects (XTW: 50.7%, NTW: 33.6%) • PMR: XTW > NT for MR reduction, w longer leaflets, large prolapse or wider jets, calcified leaflets or annulus and Barlow's or bileaflet prolapse. • SMR: NTW = XTW clips. From expand G4 #PCRLV

#PCRLV Tendyne Expanded Clinical 🎯 Low-rate of device-related adverse events 🎯 Reliable and sustainable MR elimination in >99% patients 🎯 All-cause 1 year mortality 30.8% 🎯 Procedure- or device-related 1-year mortality 15.7% 🎯 Risk factors mortality: PHT, age Small LV

Great kick-off talk by ⁦@dralisonduncan⁩ at the Berlin Edwards meeting.

#pcrtricuspid working group. Lots of ideas and lots of fun with colleagues

Right ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing transcatheter tricuspid valve repair via @PCRonline

Right ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing transcatheter tricuspid valve repair via @PCRonline

Join now for excellent teaching on TR #pcr #tricuspid

The nephrology fellowship interview

#CVCT2021 excellent summary by Dr Hahn (@hahn_rt ) on the issues/questions we need to consider in trials for treatment of tricuspid regurgitation @m_taramasso @drmaisano @FaiezZANNAD

Read the STS-ACC TVT Registry New Mitral Report: https://t.co/w4GO5hYUR3 Mortality decreased for TEER at 30 days (5.6%-4.1%), 1 year (27.4%-22.0%). Mitral valve-in-valve 30-day mortality rate 3.9%.@Mmack555 @VinodThourani @djc795 @NimeshDesaiMD @JACCJournals @SCAI @ACCinTouch